Saturday 17 October 2026
Export SOPH’s income statement to Excel — free account
SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
6.73
0.56
−7.68%
Follow SOPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.94 | 4.34 | 4.08 | 4.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(55.39) | (23.29) | (38.77) | (36.70) | |
P/B ratio |
5.13 | 7.71 | 6.69 | 5.32 | |
Price to Tangible BV |
9.07 | 35.70 | 28.03 | 12.41 | |
EV/Sales |
4.27 | 4.14 | 3.81 | 3.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.26) | (8.35) | (8.20) | (7.55) | |
EV/FCF |
(8.91) | (8.04) | (8.04) | (7.44) | |
Quick Ratio |
2.38 | 1.71 | 1.69 | 2.44 | |
Current Ratio |
2.69 | 2.06 | 1.96 | 2.80 | |
Net Debt/EBITDA |
3.48 | 1.21 | 1.40 | 2.20 | |
Debt/Assets |
24.20% | 30.47% | 29.28% | 29.11% | |
Debt/Equity |
0.58 | 1.05 | 1.01 | 0.78 | |
Asset Turnover |
0.46 | 0.53 | 0.49 | 0.43 | |
Operating CF/Net income |
0.34 | 0.78 | 0.42 | 0.44 | |
Capex/Depreciation |
(0.05) | (0.33) | (0.09) | (0.10) | |
Interest Coverage |
(12.38) | (10.37) | (11.07) | (10.74) | |
Research and Development Expense of Revenue |
37.46% | 43.62% | 39.33% | 41.45% | |
Selling, General and Administrative Expense of Revenue |
113.20% | 104.08% | 113.57% | 115.91% | |
Intangible Assets out of Total Assets |
0.18 | 0.23 | 0.22 | 0.21 | |
Share Based Compensation of Revenue |
19.27% | 15.28% | 17.82% | 21.30% | |
Graham Net Nets |
0.05 | (0.04) | (0.05) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.93%) | (23.90%) | (25.12%) | (23.59%) | |
Free Cash Flow Yield |
(9.69%) | (11.87%) | (11.61%) | (12.10%) | |
Revenue per Share |
0.32 | 0.30 | 0.32 | 0.29 | |
Operating CF per Share |
(0.10) | (0.21) | (0.12) | (0.13) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.23) | (0.12) | (0.13) | |
Cash per Share |
1.46 | 0.92 | 1.04 | 1.20 | |
Shareholders Equity per Share |
1.13 | 0.64 | 0.70 | 0.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.13 | 0.64 | 0.70 | 0.90 | |
Free Cash Flow |
(7.84) | (16.03) | (8.36) | (9.03) | |
Working Capital |
86.21 | 49.22 | 48.55 | 66.55 | |
Capital Expenditures |
(0.15) | (0.91) | (0.22) | (0.24) | |
Net Current Asset Value |
22.05 | (15.50) | (16.81) | 0.71 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.04 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.81 | 12.50 | 11.22 | 9.11 | |
Average Payables |
9.82 | 8.64 | 7.09 | 5.96 | |
Average Inventory |
6.65 | 6.07 | 6.11 | 6.58 | |
Average Assets |
187.99 | 151.86 | 159.17 | 170.53 | |
Average Common Equity |
79.91 | 65.65 | 71.82 | 87.10 |
Columns are period end dates